CGNSF (Cognetivity Neurosciences) Change In Working Capital : $-0.46 Mil (TTM As of Oct. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Change In Working Capital?

Cognetivity Neurosciences's change in working capital for the quarter that ended in Oct. 2023 was $0.54 Mil.

Cognetivity Neurosciences's change in working capital for the fiscal year that ended in Jan. 2023 was $0.15 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Cognetivity Neurosciences Change In Working Capital Historical Data

The historical data trend for Cognetivity Neurosciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences Change In Working Capital Chart

Cognetivity Neurosciences Annual Data

Trend

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Change In Working Capital

Get a 7-Day Free Trial

-0.19

0.57

-0.14

4.71

0.15

Cognetivity Neurosciences Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Change In Working Capital	Get a 7-Day Free Trial															1.17	-0.29	-0.64	-0.07	0.54

Cognetivity Neurosciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Cognetivity Neurosciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognetivity Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

1UB:Germany CGN:Canada

Address

800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6

Website

https://www.cognetivity.com

Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences Headlines

From GuruFocus

Three Companies Using AI and Innovation to Lead Healthcare Sector

By ACCESSWIRE AccessWire • 04-12-2019

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire • 04-12-2019